SCHEMBL3780573

SCHEMBL3780573

O=C(NC1CCN(CC(=O)N2CCN(C3CCC3)CC2)C1)c1cccc(Oc2ccccc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.54
NPC1 O15118 1/20 0.53
MCHR1 Q99705 4/20 0.52
CCR3 P51677 1/20 0.51
HRH3 Q9Y5N1 3/20 0.48
DRD2 P14416 1/20 0.48
DRD4 P21917 1/20 0.48
HTR7 P34969 1/20 0.47
KMT2A Q03164 3/20 0.47
USP30 Q70CQ3 2/20 0.46
SLC2A1 P11166 1/20 0.46
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
CYP1A2 P05177 1/20 0.45
POLB P06746 1/20 0.45
HSP90AA1 P07900 1/20 0.45
HSP90AB1 P08238 1/20 0.45
HSPA1A P0DMV8 1/20 0.45
CYP2D6 P10635 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3768127 0.92 KMT2A (0.54) NPC1HRH3DRD2DRD4KMT2A
SCHEMBL3762907 0.90 MCHR1 (0.58) MCHR1CCR3KMT2AKDM4EMEN1
SCHEMBL3774004 0.89 DRD2 (0.51) MCHR1HRH3DRD2DRD4KMT2A
SCHEMBL3765339 0.89 HPGD (0.56) MCHR1HTR7KMT2AALDH1A1RAB9A
SCHEMBL3761262 0.86 KMT2A (0.61) PKMNPC1HRH3KMT2AUSP30
SCHEMBL3762917 0.85 USP2 (0.52) NPC1DRD2DRD4KMT2AMEN1
SCHEMBL3767649 0.85 DRD4 (0.56) MCHR1DRD4
SCHEMBL3773750 0.83 DRD2 (0.61) NPC1DRD2DRD4KMT2AMEN1
SCHEMBL3774792 0.83 HPGD (0.60) MCHR1CCR3KMT2AMEN1ALDH1A1
SCHEMBL3762894 0.83 KMT2A (0.57) MCHR1DRD4KMT2AKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 PKM 219/4885NPC1 3462/4885MCHR1 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.